BEMARA

Bemarituzumab in patients with FGFR2b-positive advanced or metastatic
adenocarcinoma of the stomach or gastroesophageal junction, who failed at
least one prior line of palliative chemotherapy
- The IKF-AIO Phase IIa BEMARA trial

Die Studie eignet sich für: metastasiertes Adenokarzinom des Magens oder des gastroösophagealen Übergangs